My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 647

    1.

    Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.

    Haas JS, Phillips KA, Gerstenberger EP, Seger AC.

    Ann Intern Med. 2005 Jun 7;142(11):891-7.PMID: 15941695 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Employer drug benefit plans and spending on prescription drugs.

    Joyce GF, Escarce JJ, Solomon MD, Goldman DP.

    JAMA. 2002 Oct 9;288(14):1733-9. Erratum in: JAMA 2002 Nov 20;288(19):2409. PMID: 12365957 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Characteristics of older adults who meet the annual prescription drug expenditure threshold for medicare medication therapy management programs.

    Daniel GW, Malone DC.

    J Manag Care Pharm. 2007 Mar;13(2):142-54.PMID: 17330975 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Summaries for patients. Potential savings with substitution of generic drugs for brand-name drugs.

    [No authors listed]

    Ann Intern Med. 2005 Jun 7;142(11):I30. No abstract available. PMID: 15941691 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.

    Fischer MA, Avorn J.

    Pharmacoepidemiol Drug Saf. 2004 Apr;13(4):207-14.PMID: 15255087 [PubMed - indexed for MEDLINE]Related articles

    6.

    Generic script share and the price of brand-name drugs: the role of consumer choice.

    Rizzo JA, Zeckhauser R.

    Int J Health Care Finance Econ. 2009 Sep;9(3):291-316. Epub 2009 Jan 8.PMID: 19130220 [PubMed - indexed for MEDLINE]Related articles

    7.

    Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.

    Tseng CW, Brook RH, Keeler E, Mangione CM.

    JAMA. 2003 Jul 9;290(2):222-7.PMID: 12851277 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    What's in a name? Use of brand versus generic drug names in United States outpatient practice.

    Steinman MA, Chren MM, Landefeld CS.

    J Gen Intern Med. 2007 May;22(5):645-8.PMID: 17443372 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Potential savings from generic prescribing and generic substitution in South Africa.

    Karim SS, Pillai G, Ziqubu-Page TT, Cassimjee MH, Morar MS.

    Health Policy Plan. 1996 Jun;11(2):198-205.PMID: 10158460 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Outpatient prescription drug utilization and expenditure patterns of noninstitutionalized aged Medicare beneficiaries.

    LaVange LM, Silverman HA.

    Natl Med Care Util Expend Surv B. 1987 Apr;(12):1-43.PMID: 10313516 [PubMed - indexed for MEDLINE]Related articles

    11.

    Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.

    Fischer MA, Avorn J.

    Health Serv Res. 2003 Aug;38(4):1051-63.PMID: 12968816 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings.

    Gellad WF, Schneeweiss S, Brawarsky P, Lipsitz S, Haas JS.

    J Gen Intern Med. 2008 Sep;23(9):1435-40. Epub 2008 Jun 26.PMID: 18581187 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    The insurance effect on prescription drug expenditures among the elderly: findings from the 1997 Medical Expenditure Panel Survey.

    Curtis LH, Law AW, Anstrom KJ, Schulman KA.

    Med Care. 2004 May;42(5):439-46.PMID: 15083104 [PubMed - indexed for MEDLINE]Related articles

    14.

    Consumer perceptions of risk and required cost savings for generic prescription drugs.

    Ganther JM, Kreling DH.

    J Am Pharm Assoc (Wash). 2000 May-Jun;40(3):378-83.PMID: 10853539 [PubMed - indexed for MEDLINE]Related articles

    15.

    Dispensing pattern of generic and brand-name drugs in children.

    Chen AY, Wu S.

    Ambul Pediatr. 2008 May-Jun;8(3):189-94. Epub 2008 Apr 11.PMID: 18501866 [PubMed - indexed for MEDLINE]Related articles

    16.

    Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending.

    Kesselheim AS, Fischer MA, Avorn J.

    Health Aff (Millwood). 2006 Nov-Dec;25(6):1637-47.PMID: 17102189 [PubMed - indexed for MEDLINE]Related articles

    17.

    Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.

    Nunn AS, Fonseca EM, Bastos FI, Gruskin S, Salomon JA.

    PLoS Med. 2007 Nov 13;4(11):e305.PMID: 18001145 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.

    LeLorier J, Duh MS, Paradis PE, Latrémouille-Viau D, Lefebvre P, Manjunath R, Sheehy O.

    Curr Med Res Opin. 2008 Apr;24(4):1069-81. Epub 2008 Feb 29.PMID: 18315941 [PubMed - indexed for MEDLINE]Related articles

    19.

    Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit.

    Spence MM, Hui R, Chan J.

    J Manag Care Pharm. 2006 Jun;12(5):377-82.PMID: 16792444 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    The association of insurance type with costs of dispensed drugs.

    Mott DA, Kreling DH.

    Inquiry. 1998 Spring;35(1):23-35.PMID: 9597015 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity